Catalyst

Slingshot members are tracking this event:

AbbVie commences Phase 3 trial of ABT-494 for rheumatoid arthritis, expected completion mid-2017

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
ABBV

100%

Additional Information

Additional Relevant Details "In January 2016, AbbVie announced the commencement of a Phase 3 clinical trial program to study the use of AbbVie's once-daily formulation of ABT-494, its internally developed investigational selective Janus Kinase 1 (JAK-1) inhibitor, for the treatment of rheumatoid arthritis."  The study is estimated to complete in June 2017.  
https://www.clinical...
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Phase 3 Study, Abt-494, Rheumatoid Arthritis